{"cdcTestId":"2015-0013","testcaseName":"Zoster: Zoster Dose administered at 50 years of age","vaccineGroup":"ZOSTER","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on age","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1972-10-19T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"ZOSTAVAX","cvx":"121","mvx":"MSD","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"2","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"ZOSTAVAX","cvx":"121","mvx":"MSD","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2015-06-23T00:00:00","dateUpdated":"2018-04-19T07:30:45.583","generalDescription":"This test case describes when a patient is administered ZVL at age 50 years, that the first dose of the RZV vaccine should be forecasted at 8 weeks later.","changedInVersion":"3.4","reasonForChange":"V3.4: Test case updated to accommodate new ACIP Zoster recommendations.\nV2.0: New test case for version 2.0 which expanded scope into Adult recommendations"}